Evidence That Lymphangiomyomatosis Is Caused by TSC2 Mutations: Chromosome 16p13 Loss of Heterozygosity in Angiomyolipomas and Lymph Nodes from Women with Lymphangiomyomatosis  by Smolarek, Teresa A. et al.
Am. J. Hum. Genet. 62:810–815, 1998
810
Evidence That Lymphangiomyomatosis Is Caused by TSC2 Mutations:
Chromosome 16p13 Loss of Heterozygosity in Angiomyolipomas and
Lymph Nodes from Women with Lymphangiomyomatosis
Teresa A. Smolarek,1 Lisa L. Wessner,3 Francis X. McCormack,2 Johanna C. Mylet,3
Anil G. Menon,1 and Elizabeth Petri Henske3
Departments of 1Molecular Genetics, Biochemistry and Microbiology, and 2Medicine, University of Cincinnati, Cincinnati; and 3Department
of Medical Oncology, Fox Chase Cancer Center, Philadelphia
Summary
Lymphangiomyomatosis (LAM) is a rare disease, of un-
known etiology, affecting women almost exclusively.
Lung transplantation is the only consistently effective
therapy for LAM. Microscopically, LAM consists of a
diffuse proliferation of smooth muscle cells. LAM can
occur without evidence of other disease (referred to as
“sporadic LAM”) or in association with tuberous scle-
rosis complex (TSC). TSC is an autosomal dominant
tumor suppressor gene syndrome characterized by sei-
zures, mental retardation, and tumors in the brain, heart,
skin, and kidney. Renal angiomyolipomas occur in
∼50% of sporadic LAM patients and in 70% of TSC
patients. Loss of heterozygosity (LOH) in the chromo-
somal region for the TSC2 gene occurs in 60% of TSC-
associated angiomyolipomas. Because of the similar pul-
monary and renal manifestations of TSC and sporadic
LAM, we hypothesized that LAM and TSC have a com-
mon genetic basis. We analyzed renal angiomyolipomas,
from 13 women with sporadic LAM, for LOH in the
regions of the TSC1 (chromosome 9q34) and TSC2
(chromosome 16p13) genes. TSC2 LOH was detected
in seven (54%) of the angiomyolipomas. We also found
TSC2 LOH in four lymph nodes from a woman with
retroperitoneal LAM. No TSC1 LOH was found. Our
findings indicate that the TSC2 gene may be involved
in the pathogenesis of sporadic LAM. However, genetic
transmission of LAM has not been reported. Women
with LAM may have low-penetrance germ-line TSC2
mutations, or they may be mosaic, with TSC2mutations
in the lung and the kidney but not in other organs.
Received December 2, 1997; accepted for publication February 12,
1998; electronically published March 18, 1998.
Address for correspondence and reprints: Dr. Elizabeth PetriHenske,
Fox Chase Cancer Center, 7701 Burholme Avenue, Philadelphia, PA
19111. E-mail: EPHenske@fccc.edu
 1998 by The American Society of Human Genetics. All rights reserved.
0002-9297/98/6204-0012$02.00
Introduction
Lymphangiomyomatosis (LAM), which affects women
almost exclusively, is a rare disease of unknown etiology
that was first described ∼60 years ago (Van Stossel
1937). The average age at onset of symptoms, which
include shortness of breath (67%), lung collapse (25%),
coughing (12%), and chest pain (10%), is 33 years (Tay-
lor et al. 1990; Johnson et al. 1993). Chest x-rays typ-
ically reveal a diffuse interstitial infiltrate, with no pre-
dominance in any one lung zone. Although most LAM
is pulmonary, cases with retroperitoneal, pelvic, or per-
irenal involvement in lymph nodes and extranodal sites
have been reported (Torres et al. 1995). LAM usually is
diagnosed by open lung biopsy. Microscopically, there
is cystic distortion of the normal pulmonary architecture
by an atypical smooth muscle infiltrate (fig. 1). Most
patients have a slowly declining clinical course (Taylor
et al. 1990). Lung transplantation is the only effective
therapy for patients with end-stage disease (Boehler et
al. 1996; Kalassian et al. 1997).
LAM is diagnosed in ∼1/1,000,000 people, in both
Europe and the United States. The actual incidence is
likely to be higher, however, since LAM is difficult to
distinguish clinically from other pulmonary diseases and
is often misdiagnosed as asthma, chronic obstructive
pulmonary disease, or bronchitis (Taylor et al. 1990).
LAM can occur as an isolated disorder (here referred
to as “sporadic LAM”) or in association with tuberous
sclerosis complex (TSC). TSC is an autosomal dominant
disorder characterized by seizures, mental retardation,
and hamartomatous tumors of the brain, heart, kidney,
lung, and skin. These tumors include cerebral cortical
tubers, cardiac rhabdomyomas, renal angio-
myolipomas, LAM, and facial angiofibromas. LAM af-
fects 4.6% of women with TSC (Castro et al. 1995), an
incidence that is ∼20,000# that of the general popu-
lation. Among patients with TSC, LAM is the third-
most-frequent cause of TSC-related death, after renal
disease and brain tumors (Castro et al. 1995).
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Figure 1 Histopathological similarity between the smooth muscle cells of LAM (left) and of angiomyolipomas (right). Arrows indicate
regions of smooth muscle proliferation. (Stained with hematoxylin and eosin; original magnification #40.)
Angiomyolipomas are benign tumors consisting of fat,
smooth muscle (fig. 1), and vascular elements. Renal
angiomyolipomas occur in two-thirds of patients with
TSC (Bjornsson et al., in press) and in ∼50% of women
with sporadic LAM (Kerr et al. 1993; Bernstein et al.
1995; Maziak et al. 1996). In contrast to the angiom-
yolipomas associated with TSC, which are usually mul-
tiple and bilateral, angiomyolipomas associated with
sporadic LAM tend to be solitary and asymptomatic.
Two genes are associated with TSC: TSC2 on chro-
mosome 16p13 (European Chromosome 16 Tuberous
Sclerosis Consortium 1993) and TSC1 on chromosome
9q34 (Van Slegtenhorst et al. 1997). Patients with TSC2
disease appear to have a higher risk of mental retarda-
tion than do those with TSC1 disease (Jones et al. 1997).
Of the patients with a family history of TSC, 50% show
genetic linkage to TSC1 and 50% to TSC2 (Povey et al.
1994). However, two-thirds of TSC patients have no
prior family history of the disease and are believed to
represent new mutations. Germ-line TSC1 and TSC2
mutations appear to be inactivating (European Chro-
mosome 16 Tuberous Sclerosis Consortium 1993; Van
Slegtenhorst et al. 1997), and loss of heterozygosity
(LOH) occurs in TSC tumors (Carbonara et al. 1994;
Green et al. 1994a, 1994b; Henske et al. 1995, 1996),
suggesting that TSC1 and TSC2 are tumor suppressor
genes.
Because women with TSC and those with sporadic
LAM have similar lung and renal disease, we hypothe-
sized that women with sporadic LAM have mutations
in the TSC1 or the TSC2 gene, despite the absence of
CNS, dermatologic, or other manifestations of TSC. We
analyzed 13 LAM-associated angiomyolipomas and five
lymph nodes containing LAM, for LOH in the chro-
mosomal regions of the TSC1 and TSC2 genes.
Material and Methods
This study was approved by the Institutional Review
Board of the Fox Chase Cancer Center. All patients had
typical manifestations of pulmonary LAM (dyspnea,
pneumothoraces, and/or chylous effusions), except for
patient 500, who had extensive abdominal and retro-
peritoneal LAM. Five nodes from this patient were se-
lected for analysis. One node (L1) contained lympho-
cytes along with smooth muscle cells. The other four
nodes (L2–L5) contained almost exclusively smooth
muscle cells. For the angiomyolipomas, DNA was ex-
tracted from unstained paraffin-embedded tissue in 50
mM KCl, 10 mM Tris (pH 8.3), 1.5 mM MgCl2, 100
mg BSA/ml, 0.45% Tween 20, 0.45% Nonidet P-40, and
100 mg proteinase K/ml. A 2-ml aliquot of DNA was
used in a 20-ml PCR reaction. Control genomic DNA
was obtained from histologically normal tissue. For the
LAM-associated lymph nodes, a random 15-nucleotide
preamplification step was performed before the specific
PCR reaction (Zhang et al. 1992). For the preamplifi-
cation, DNA was purified by use of phenol-chloroform
extraction and was resuspended in 10 ml water. The
DNA was amplified by use of a random primer (Operon
Technologies) at a 2-mM final concentration in a total
volume of 100 ml, for 50 cycles consisting of 94C for
1 min, 37C for 2 min, a 37–55C ramp at 10 s/, and
55C for 4 min, with a final extension at 72C for 5
min. For the specific amplifications, we used three mi-
crosatellite markers on chromosome 9q34 that are
within 500 kb of TSC1—D9S149, D9S1198, and
D9S1199 (Henske et al. 1993, 1996)—and four markers
on chromosome 16p13 that are within 600 kb of
TSC2—Kg8, D16S525, D16S283, and D16S291 (Shen
et al. 1994; Snarey et al. 1994). PCR was performed
812 Am. J. Hum. Genet. 62:810–815, 1998
Table 1
Results of LOH Analyses and Clinical Examinations of Eyes, Skin,
and Brain for Evidence of TSC, for 14 Women with LAM
PATIENT
TSC2
LOHa
TSC1
LOHa
CLINICAL EVIDENCE OF TSCb
Eye Skin Brain CT/MRI
367    Normal
423    Normal
432     Normal
436     Normal
437    Normal
443     Normal
480    Normal
481    Normal
487    Not performed
489     Normal
490    Not performed
491    Normal
492     Normal
500    Normal
a A plus sign () indicates presence of LOH, and a minus sign ()
indicates absence of LOH.
b A minus sign () indicates that a specific examination for retinal
hamartomas (“Eye”) or for dermatologic manifestations (“Skin”) was
performed, and no evidence of TSC was detected.
Figure 2 Examples of LOH at chromosome 16p13 markers D16S291, D16S283, and Kg8, in angiomyolipomas from patients 367, 436,
487, and 492. K  normal kidney; and A  angiomyolipoma. Horizontal lines indicate the upper band of each allele in the normal kidney.
Arrows indicate the “lost” alleles in the angiomyolipomas.
with [32P]dGTP in the reaction mix. PCR products were
resolved by denaturing 8-M urea-polyacrylamide gel
electrophoresis and were visualized by autoradiography.
LOH was determined by visual inspection of the relative
intensities of the bands, with comparison to the pattern
in normal DNA from the same individual (Henske and
Kwiatkowski 1998). All results were repeated at least
twice for confirmation.
Results
Seven (54%) of the 13 angiomyolipomas showed
LOH in the TSC2 region of chromosome 16p13 (table
1). Representative examples of chromosome 16p13
LOH are shown in figure 2. No LOH was detected in
the TSC1 region of chromosome 9q34. The markers
typed for each tumor and the results of the LOH analysis
are given in table 2. Four retroperitoneal lymph nodes
containing LAM, from patient 500, showed TSC2 LOH
(fig. 3). To control for the specificity of the lymph-node
LOH results, which were obtained by a preamplification
using a random primer, multiple normal DNA samples
from patient 500 were amplified by use of the pream-
plification step. No evidence of allelic loss was seen. As
an additional control, the preamplification step, using
multiple chromosome 16p13 and 9q34 markers, was
used on eight of the angiomyolipoma DNA samples,
with results that were identical to those obtainedwithout
preamplification.
No patient in this study had a family history of either
TSC or LAM, and no patient had any clinical signs or
symptoms of TSC. The degree to which individual pa-
tients were screened for TSC by dermatologic exami-
nations, ophthalmologic examinations, or brain imaging
is given in table 1. For all patients, except patients 487
and 490, brain computed tomography (CT) ormagnetic-
resonance imaging (MRI) scans were performed to ex-
clude a diagnosis of TSC. As indicated in table 1, some
patients also had ophthalmologic examinations that
showed no evidence of retinal hamartomas.
Discussion
LAM is a rare, nonfamilial, progressive lung disease
affecting women. The distinctive histological pattern of
diffuse smooth muscle proliferation and cystic degen-
eration of the lung interstitium also is seen in ∼5% of
women with TSC. Patients with sporadic LAM do not
have the neurological, ocular, or dermatologic manifes-
tations of TSC but frequently have renal angiomyoli-
pomas. These similarities have led to speculation that
LAM and TSC have a common pathogenic basis (Corrin
et al. 1975; Bonetti and Chiodera 1996).
Here we report, for the first time, that LOH in the
region of TSC2 occurs in LAM-associated renal angio-
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Table 2
LOH Results for Individual Markers on Chromosomes 16p13 and 9q34
Patient Tissuea D16S283 D16S291 Kg8 D16S525 D9S149 D9S1199 D9S1198
367 AML ) 2 LOH LOH 2 2 )
423 AML 1 2 1 1 ) 2 )
432 AML ) LOH LOH LOH 2 ) )
436 AML 1 LOH LOH LOH 2 1 2
437 AML 1 LOH LOH 1 2 1 2
443 AML 1 2 1 2 2 2 2
480 AML 1 2 1 2 2 2 1
481 AML 1 2 1 1 2 2 )
487 AML 1 1 LOH 1 ) ) 1
489 AML 1 2 1 2 1 2 )
490 AML ) ) 1 LOH 2 2 )
491 AML ) 1 1 2 2 ) )
492 AML LOH LOH 1 LOH 2 ) 1
500 L1 2 2 1 2 2 ) )
L2 LOH LOH 1 LOH 2 ) )
L3 LOH LOH 1 LOH 2 ) )
L4 LOH LOH 1 LOH 2 ) )
L5 LOH LOH 1 LOH 2 ) )
NOTE.—1  homozygous marker; and 2  heterozygous marker without LOH. An ellipsis ())
indicates that the marker was not typed for that patient. The markers are listed in centromeric-to-
telomeric order; the TSC2 gene is between markers Kg8 and D16S525, and the TSC1 gene is between
markers D9S149 and D9S1199.
a AML  angiomyolipoma.
Figure 3 LOH at chromosome 16p13 marker D16S291, in re-
troperitoneal lymph nodes (L1–L5) from patient 500. Each allele is
represented by a ladder of three bands. Horizontal lines indicate the
upper band of each allele in normal DNA (N). Heterozygosity is re-
tained in L1. The arrow indicates the “lost” lower alleles in L2–L5.
myolipomas and in lymph nodes containing LAM. We
detected LOH in 7 (54%) of 13 angiomyolipomas from
women with LAM and in four lymph nodes from one
female patient with retroperitoneal LAM. In previous
work, we found that 56% of TSC-associated angiom-
yolipomas show LOH at either the TSC1 or the TSC2
locus (Henske et al. 1996), compared with 10% of spo-
radic angiomyolipomas (i.e., those not associated with
TSC or LAM) (Henske et al. 1995). The difference be-
tween the incidence of TSC2 LOH in LAM-associated
angiomyolipomas and the incidence of LOH in sporadic
angiomyolipomas is statistically significant ( , byP ! .001
use of Fisher’s exact test). We and others have found
that benign angiomyolipomas have a low incidence of
genomic instability and random LOH (Carbonara et al.
1996; Henske et al. 1996).
The TSC2 LOH in the angiomyolipomas fromwomen
with LAM is consistent with a TSC2 mutation in the
remaining allele. In TSC (Carbonara et al. 1994) and in
other germ-line tumor suppressor gene disorders (Collins
et al. 1995; Cornelis et al. 1995), the LOH pattern has
been consistent with loss of the wild-type allele. In spo-
radic tumors of many types, LOH has been predictive
of somatic mutation in the remaining allele. For ex-
ample,MEN1mutations were found in 7 of 13 sporadic
parathyroid tumors with chromosome 11q13 LOH but
in 0 of 20 tumors without 11q13 LOH (Heppner et al.
1997). Because LOH patterns are predictive of alleles
containing somatic mutations, LOH also has been used
to augment or complement linkage data from pedigrees
with inherited cancer-predisposition syndromes (Lust-
bader et al. 1995; Hemminki et al. 1997; Rohde et al.
1997).
LOH was found only on chromosome 16p13 (TSC2)
in the LAM-associated angiomyolipomas. This may in-
dicate that TSC2 mutations are more likely to cause
sporadic LAM than are TSC1 mutations. Alternatively,
angiomyolipomas resulting from TSC2 mutations may
be more likely to require surgical removal, either because
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they are larger than angiomyolipomas resulting from
TSC1mutations or because they are more likely to bleed.
It is not known whether Knudson’s two-hit tumor
suppressor gene model (Knudson 1971) applies to the
pulmonary smooth muscle cells as well as to the an-
giomyolipomas of LAM patients. Because of the inter-
mingling of smooth muscle cells with normal lung pa-
renchyma, it is difficult to isolate a pure population of
pulmonary LAM smooth muscle cells for LOH analysis.
However, a common pathogenic basis for the abnormal
cellular proliferations in the lung (pulmonary LAM) and
the kidney (angiomyolipomas) is likely. The smooth
muscle cells of LAM and of angiomyolipomas appear
to be closely related on the basis of histological (fig. 1),
immunohistochemical (Chan et al. 1993), and ultra-
structural (Peyrol et al. 1992; Kaiserling et al. 1994)
criteria. In addition, the LOH in LAM-containing lymph
nodes from patient 500 indicates that the two-hit model
applies to extrarenal as well as to renal smooth muscle
cells in LAM. The LOH pattern in the four nodes with
LOH was identical (table 2), and the node without LOH
contained some contaminating normal lymphocytes.
Therefore, we were unable to determine whether the
smooth muscle cells in the separate lymph nodes resulted
from a single second-hit event or from multiple second-
hit events.
Our data support a role for TSC2 mutations in the
pathogenesis of angiomyolipomas in women with LAM.
This could indicate that both LAM and TSC are caused
by germ-line TSC2 mutations and are part of the same
disease spectrum. The fact that genetic transmission of
LAM from mother to daughter has not been reported
argues against germ-lineTSC2mutations in womenwith
LAM. If, however, these mutations have low expression
or require the interaction of specific environmental fac-
tors, such as hormonal factors, to result in smooth mus-
cle growth, it is possible that a low frequency of genetic
transmission of LAM has not yet been recognized. An
alternative explanation for our findings is that LAM pa-
tients are mosaic (Hall 1988), with inactivating TSC2
mutations in the lung and, in some cases, in the kidney
but not in skin, brain, or germ-line tissue. Cases with
apparent somatic mosaicism have been identified for
TSC (Verhoef et al. 1995) as well as for other tumor
suppressor gene syndromes (Evans et al. 1997; Lohmann
et al. 1997; Sippel et al. 1997).
In summary, we found TSC2 LOH in angiomyoli-
pomas from seven women with sporadic LAM and in
retroperitoneal lymph nodes from an eighth woman.
This is the first molecular data supporting a common
pathogenic basis for LAM and TSC. Since genetic trans-
mission of LAM has not been reported, it is possible
that LAM patients have germ-line TSC2 mutations with
limited expression or that they are mosaic for TSC2
mutations.
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